Drug repositioning framework driven by landscape analysis and competitive intelligence: A case report on Prader Willi Syndrome

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Header Abstract Content Author and article information References Comments

Version and Review History

Conference proceedings

Reviewed by Harald H. H. W. Schmidt

Record: found
Abstract: found
Conference Proceedings: found

Is Open Access

Drug repositioning framework driven by landscape analysis and competitive intelligence: A case report on Prader Willi Syndrome

Published

conference-abstract

Author(s): Manish Sarkar ¹ , Dimitrije Milunov ¹ , Nathalie Barreto Lefebvre ¹ , Soham Saha ¹

Publication date (Electronic, pub): 30 April 2024

Publisher: REPO4EU

Conference name: RExPO24

Conference date: 3-5 July 2024

Keywords: Drug repositioning, Genetic obesity, Prader Willi syndrome, GLP1 agonist, Combination therapy, Competitive landscape, Life cycle management

Bookmark

Abstract

Content

Author and article information

Conference

Publisher: REPO4EU

Publication date (Electronic, pub): 30 April 2024

Affiliations

[1 ] MedInsights SAS, Paris, France;

Author information

Manish Sarkar https://orcid.org/0000-0002-0861-888X

Soham Saha https://orcid.org/0000-0003-1173-1397

Article

DOI: 10.58647/REXPO.24003

SO-VID: bd6bd751-654c-4d3d-a8e4-acaa250b95fa

License:

Published under Creative Commons Attribution 4.0 International ( CC BY 4.0). Users are allowed to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source.

Conference name: RExPO24

Conference number: 3

Conference location: Munich, Germany

Conference date: 3-5 July 2024

History

Product

REPO4EU

References

Roessler Helen I., Knoers Nine V.A.M., van Haelst Mieke M., van Haaften Gijs. Drug Repurposing for Rare Diseases. Trends in Pharmacological Sciences. Vol. 42(4):255–267. 2021. Elsevier BV. [Cross Ref]
Jonker Anneliene Hechtelt, O’Connor Daniel, Cavaller-Bellaubi Maria, Fetro Christine, Gogou Maria, ’T Hoen Peter A. C., de Kort Martin, Stone Heather, Valentine Nivedita, Pasmooij Anna Maria Gerdina. Drug repurposing for rare: progress and opportunities for the rare disease community. Frontiers in Medicine. Vol. 11:2024. Frontiers Media SA. [Cross Ref]
Ng Nicholas Beng Hui, Low Yue Wey, Rajgor Dimple Dayaram, Low Jia Ming, Lim Yvonne Yijuan, Loke Kah Yin, Lee Yung Seng. The effects of glucagon‐like peptide (GLP)‐1 receptor agonists on weight and glycaemic control in Prader–Willi syndrome: A systematic review. Clinical Endocrinology. Vol. 96(2):144–154. 2022. Wiley. [Cross Ref]
Cassidy Suzanne B, Driscoll Daniel J. Prader–Willi syndrome. European Journal of Human Genetics. Vol. 17(1):3–13. 2009. Springer Science and Business Media LLC. [Cross Ref]
Allas Soraya, Caixàs Assumpta, Poitou Christine, Coupaye Muriel, Thuilleaux Denise, Lorenzini Françoise, Diene Gwenaëlle, Crinò Antonino, Illouz Frédéric, Grugni Graziano, Potvin Diane, Bocchini Sarah, Delale Thomas, Abribat Thierry, Tauber Maithé. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial. PLOS ONE. Vol. 13(1)2018. Public Library of Science (PLoS). [Cross Ref]
Loos Ruth J. F., Yeo Giles S. H.. The genetics of obesity: from discovery to biology. Nature Reviews Genetics. Vol. 23(2):120–133. 2022. Springer Science and Business Media LLC. [Cross Ref]

Comments

Comment on this article

[1] Roessler Helen I., Knoers Nine V.A.M., van Haelst Mieke M., van Haaften Gijs. Drug Repurposing for Rare Diseases. Trends in Pharmacological Sciences. Vol. 42(4):255–267. 2021. Elsevier BV. [Cross Ref]

[2] Jonker Anneliene Hechtelt, O’Connor Daniel, Cavaller-Bellaubi Maria, Fetro Christine, Gogou Maria, ’T Hoen Peter A. C., de Kort Martin, Stone Heather, Valentine Nivedita, Pasmooij Anna Maria Gerdina. Drug repurposing for rare: progress and opportunities for the rare disease community. Frontiers in Medicine. Vol. 11:2024. Frontiers Media SA. [Cross Ref]

[3] Ng Nicholas Beng Hui, Low Yue Wey, Rajgor Dimple Dayaram, Low Jia Ming, Lim Yvonne Yijuan, Loke Kah Yin, Lee Yung Seng. The effects of glucagon‐like peptide (GLP)‐1 receptor agonists on weight and glycaemic control in Prader–Willi syndrome: A systematic review. Clinical Endocrinology. Vol. 96(2):144–154. 2022. Wiley. [Cross Ref]

[4] Cassidy Suzanne B, Driscoll Daniel J. Prader–Willi syndrome. European Journal of Human Genetics. Vol. 17(1):3–13. 2009. Springer Science and Business Media LLC. [Cross Ref]

[5] Allas Soraya, Caixàs Assumpta, Poitou Christine, Coupaye Muriel, Thuilleaux Denise, Lorenzini Françoise, Diene Gwenaëlle, Crinò Antonino, Illouz Frédéric, Grugni Graziano, Potvin Diane, Bocchini Sarah, Delale Thomas, Abribat Thierry, Tauber Maithé. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial. PLOS ONE. Vol. 13(1)2018. Public Library of Science (PLoS). [Cross Ref]

[6] Loos Ruth J. F., Yeo Giles S. H.. The genetics of obesity: from discovery to biology. Nature Reviews Genetics. Vol. 23(2):120–133. 2022. Springer Science and Business Media LLC. [Cross Ref]

Drug repositioning framework driven by landscape analysis and competitive intelligence: A case report on Prader Willi Syndrome

Conference

Affiliations

Author information

Article

History

Product

Categories

Comment on this article